Evidence map›Paper›PMID 24465865›Full record

ArticlePloS one2014

Tracking molecular recognition at the atomic level with a new protein scaffold based on the OB-fold.

John D Steemson, Matthias Baake, Jasna Rakonjac, Vickery L Arcus, Mark T Liddament

Abstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Peptide aptamers: development and applications.Current topics in medicinal chemistry · 2015
    Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

John D SteemsonDepartment of Biological Sciences, University of Waikato, Hamilton, New Zealand.
Matthias BaakeDepartment of Biological Sciences, University of Waikato, Hamilton, New Zealand.
Jasna RakonjacInstitute of Molecular BioSciences, Massey University, Palmerston North, New Zealand.
Vickery L ArcusDepartment of Biological Sciences, University of Waikato, Hamilton, New Zealand.
Mark T LiddamentOBodies Limited, Hamilton, New Zealand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The OB-fold is a small, versatile single-domain protein binding module that occurs in all forms of life, where it binds protein, carbohydrate, nucleic acid and small-molecule ligands. We have exploited this natural plasticity to engineer a new class of non-immunoglobulin alternatives to antibodies with unique structural and biophysical characteristics. We present here the engineering of the OB-fold anticodon recognition domain from aspartyl tRNA synthetase taken from the thermophile Pyrobaculum aerophilum. For this single-domain scaffold we have coined the term OBody. Starting from a naïve combinatorial library, we engineered an OBody with 3 nM affinity for hen egg-white lysozyme, by optimising the affinity of a naïve OBody 11,700-fold over several affinity maturation steps, using phage display. At each maturation step a crystal structure of the engineered OBody in complex with hen egg-white lysozyme was determined, showing binding elements in atomic detail. These structures have given us an unprecedented insight into the directed evolution of affinity for a single antigen on the molecular scale. The engineered OBodies retain the high thermal stability of the parental OB-fold despite mutation of up to 22% of their residues. They can be expressed in soluble form and also purified from bacteria at high yields. They also lack disulfide bonds. These data demonstrate the potential of OBodies as a new scaffold for the engineering of specific binding reagents and provide a platform for further development of future OBody-based applications.

Indexed as

Protein EngineeringAmino Acid SequenceAnimalsAnticodonArchaeal ProteinsAspartate-tRNA LigaseBinding SitesChickensCrystallography, X-RayModels, MolecularMolecular Sequence DataMuramidaseProtein ConformationProtein StabilityPyrobaculumAnticodonArchaeal ProteinsAspartate-tRNA Ligasehen egg lysozymeMuramidase

Identifiers

PMID24465865
PMCPMC3896448

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.